New triple therapy targets hard-to-treat belly fluid in advanced cancer patients
NCT ID NCT07196540
First seen Oct 31, 2025 · Last updated Apr 29, 2026 · Updated 25 times
Summary
This study tests a new treatment for people with advanced digestive tract cancers that cause fluid buildup in the belly (malignant ascites) after standard treatments have stopped working. The treatment combines a modified protein (rmhTNF-NC) injected into the belly, an immunotherapy drug (tislelizumab), and targeted radiation. The goal is to see if this combination can shrink or eliminate the fluid and improve outcomes. About 78 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIGESTIVE SYSTEM NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.